Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 07:30 ET | Source: Ocugen

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
September 01, 2022 07:30 ET | Source: Ocugen

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
August 12, 2022 07:30 ET | Source: Ocugen

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
August 05, 2022 07:30 ET | Source: Ocugen

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

Dosing patients in U.S. Phase 2/3 COVAXIN™ (BBV152) clinical trialCompleted dosing of patients in Cohort 1 of OCU400 gene therapy product candidateExpanding product pipeline with the regenerative...
July 29, 2022 07:30 ET | Source: Ocugen

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and...
June 21, 2022 07:00 ET | Source: Ocugen

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American...
June 14, 2022 07:00 ET | Source: Ocugen

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies,...
June 13, 2022 07:00 ET | Source: Ocugen

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell...
June 09, 2022 18:17 ET | Source: Ocugen

Ocugen, Inc. to Present at BIO International Convention 2022

MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
May 24, 2022 07:11 ET | Source: Ocugen

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE...